Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease

Rossi, Sabrina; Basso, Michele; Strippoli, Antonia; Dadduzio, Vincenzo; Cerchiaro, Eleonora; Barile, Rosalba; D’Argento, Ettore; Cassano, Alessandra; Schinzari, Giovanni; Barone, Carlo

doi:10.1016/j.clbc.2015.03.010

Cited by 68 publications

(67 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies reported status change rates of 10.3-30.4% for ER and 16-54.3% for PR [5,7,8]. Our study showed an ER status change rate for surgical specimens of 3%, much lower than previously reported rates, while the PR status change rate was 24%, similar to other studies.…”

Section: Discussionsupporting

confidence: 84%

“…The expression of hormone receptors is associated with better prognosis and is important for predicting the response to adjuvant endocrine therapy [4]. Although HER2 positivity is related to a shortened recurrence-free survival in ER-positive patients and also worse prognosis [5], anti-HER2-targeted therapies have demonstrated effectiveness in HER2-positive primary and metastatic breast cancers.…”

Section: Introductionmentioning

confidence: 99%

“…Therefore, it is crucial to know if there is discordance between the primary tumor and metastases with regard to biomarkers. Indeed, previous study reports of discordance between the primary tumor and metastases regarding biomarker status were in the range of 10.3-30.4% for ER, 16-54.3% for PR and 0-34% for HER2 [4,5,7,8,9,10]. The College of American Pathologists (CAP) recommends retesting of biomarkers of metastatic breast cancer because the results may affect the patient's management [11].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Correlation of Expression of Breast Biomarkers in Primary and Metastatic Breast Carcinomas: A Single-Institution Experience

Hou

Shen²,

Chaudhary³

et al. 2016

Acta Cytologica

View full text Add to dashboard Cite

Objective: Changes in the status of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) in metastatic breast carcinomas are frequently reported. We examined the change in the status of biomarkers in metastatic breast carcinomas. Study Design: This study cohort was composed of 137 metastatic breast carcinomas (58 surgical and 79 cytological specimens) with existing primary tumors during a study period from 2013 to 2015. Results: The overall change rates in metastases were 9, 21 and 6% for ER, PR and HER2, respectively. All changes were from positive in the primary tumor to negative in the metastases. The ER change rate was significantly higher in the cytological than in the surgical metastases. Six of 14 cytological metastases with positive HER2 in primary tumors showed a change in HER2 status, including 5 fluid specimens and 1 fine-needle aspiration (FNA); the other 8 had no change in HER2 status, and included 7 FNAs and 1 fluid specimen. Conclusion: The significant percentage of cases with a change in biomarker status supports the recommendation by the College of American Pathologists to test breast biomarkers in metastases. HER2 status change was mostly identified in fluid specimens; however, the small sample size in our cohort and the fact that HER2 fluorescence in situ hybridization was not performed may warrant further studies.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Correlation of Expression of Breast Biomarkers in Primary and Metastatic Breast Carcinomas: A Single-Institution Experience

Hou

Shen²,

Chaudhary³

et al. 2016

Acta Cytologica

View full text Add to dashboard Cite

show abstract

“…Metastatic sites include liver, bones, lung, pancreas, softtissues, and brain [42].Whenmetastatic disease is suspected, especially in the case of metachronous metastases developed after a long latency period from the treatment of the primary tumor, a biopsy of the metastatic site would be useful to confirm the diagnosis and also to analyze the molecular characteristics of the disease, including immunohistochemistry markers of neuroendocrine differentiation, HER2, and hormone receptor status, given the possible heterogeneity between primary breast cancer and metastases [43].…”

Section: Treatmentmentioning

confidence: 99%

Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives

et al. 2015

View full text Add to dashboard Cite

Neuroendocrine carcinoma of the breast is considered a rare entity, and for this reason there are no data from prospective clinical trials on its optimal management. Early stage tumors are usually treated with the same strategy used for the other types of invasive breast cancer. Anthracycline-and taxane-based regimens represent the most frequently administered chemotherapy in neoadjuvant and adjuvant setting, as well as for metastatic disease, although combinations of platinum compounds and etoposide have been widely used, in particular for small-cell histology and tumors with a high proliferation index. For metastatic disease, a multimodality therapeutic strategy can be considered on an individual basis, with chemotherapy, endocrine therapy, peptide receptor radionuclide therapy, radiation therapy, surgery, or a combination of the above. In the near future, a better knowledge of the biology of these tumors will hopefully provide new therapeutic targets for personalized treatment. In this review, we discuss the current evidence and the future perspectives on diagnosis and treatment of neuroendocrine carcinoma of the breast. The Oncologist 2016;21:28-32 Implications for Practice: Neuroendocrine carcinoma of the breast (NECB) is a distinct entity of breast cancer. Clinical features and morphology are not helpful to distinguish NECB from other subtypes of breast cancer; therefore, immunohistochemistry markers for neuroendocrine differentiation, mainly chromogranin and synaptophysin, should be routinely used to confirm the diagnosis, especially in cases of mucinous or solid papillary carcinoma in which the suspicion of NECB may be relevant. Adjuvant treatment should be offered according to the same recommendations given for the other types of invasive breast cancer. An accurate diagnosis of NECB is also important in the metastatic setting, in which a multimodality approach including specific therapies such as peptide receptor radionuclide therapy can be considered.

show abstract

“…In the discordance cases, it is more frequent to have HER-2-positive conversion in metastatic sites with negative primary tumours than the opposite [4]. …”

mentioning

confidence: 99%

A Positive Conversion of Hormone Receptor Status Might Improve Survival after Liver Resection for Breast Metastases: Reply to Dr. Altundag

Ercolani¹

2018

Dig Surg

View full text Add to dashboard Cite

Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease

Cited by 68 publications

References 25 publications

Correlation of Expression of Breast Biomarkers in Primary and Metastatic Breast Carcinomas: A Single-Institution Experience

Correlation of Expression of Breast Biomarkers in Primary and Metastatic Breast Carcinomas: A Single-Institution Experience

Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives

A Positive Conversion of Hormone Receptor Status Might Improve Survival after Liver Resection for Breast Metastases: Reply to Dr. Altundag

Contact Info

Product

Resources

About